Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Clinical trial NCT04848454 · UNKNOWN

Trial details

NCT number: NCT04848454
Sponsor: Peking University First Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-negative Breast Cancer Neoadjuvant Therapy Pathological Complete Response Immunotherapy Vinorelbine Cisplatin

Start date: 2021-11-20
Primary completion: 2024-02-28
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.